These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 35529790)

  • 1. Clinicopathologic characteristics and diagnostic methods of
    Feng J; Li Y; Wei B; Guo L; Li W; Xia Q; Zhao C; Zheng J; Zhao J; Sun R; Guo Y; Brcic L; Hakozaki T; Ying J; Ma J
    Transl Lung Cancer Res; 2022 Apr; 11(4):617-631. PubMed ID: 35529790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Performance Comparison of Commonly Used Assays to Detect RET Fusions.
    Yang SR; Aypar U; Rosen EY; Mata DA; Benayed R; Mullaney K; Jayakumaran G; Zhang Y; Frosina D; Drilon A; Ladanyi M; Jungbluth AA; Rekhtman N; Hechtman JF
    Clin Cancer Res; 2021 Mar; 27(5):1316-1328. PubMed ID: 33272981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma.
    Song Z; Yu X; Zhang Y
    Lung Cancer; 2016 Nov; 101():16-21. PubMed ID: 27794403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC.
    Tan AC; Seet AOL; Lai GGY; Lim TH; Lim AST; Tan GS; Takano A; Tai DWM; Tan TJY; Lam JYC; Ng MCH; Tan WL; Ang MK; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim WT; Tan EH; Lim TKH; Tan DSW
    J Thorac Oncol; 2020 Dec; 15(12):1928-1934. PubMed ID: 32866654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer.
    Radonic T; Geurts-Giele WRR; Samsom KG; Roemen GMJM; von der Thüsen JH; Thunnissen E; Meijssen IC; Sleddens HFBM; Dinjens WNM; Boelens MC; Weijers K; Speel EJM; Finn SP; O'Brien C; van Wezel T; Cohen D; Monkhorst K; Roepman P; Dubbink HJ
    J Thorac Oncol; 2021 May; 16(5):798-806. PubMed ID: 33588111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
    Wang C; Zhang Z; Sun Y; Wang S; Wu M; Ou Q; Xu Y; Chen Z; Shao Y; Liu H; Hou P
    J Transl Med; 2022 Sep; 20(1):390. PubMed ID: 36059009
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Overbeck TR; Reiffert A; Schmitz K; Rittmeyer A; Körber W; Hugo S; Schnalke J; Lukat L; Hugo T; Hinterthaner M; Reuter-Jessen K; Schildhaus HU
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma.
    Go H; Jung YJ; Kang HW; Park IK; Kang CH; Lee JW; Ju YS; Seo JS; Chung DH; Kim YT
    Lung Cancer; 2013 Oct; 82(1):44-50. PubMed ID: 23932363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.
    Wang R; Hu H; Pan Y; Li Y; Ye T; Li C; Luo X; Wang L; Li H; Zhang Y; Li F; Lu Y; Lu Q; Xu J; Garfield D; Shen L; Ji H; Pao W; Sun Y; Chen H
    J Clin Oncol; 2012 Dec; 30(35):4352-9. PubMed ID: 23150706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers.
    Xia P; Zhang L; Li P; Liu E; Li W; Zhang J; Li H; Su X; Jiang G
    J Transl Med; 2021 Jul; 19(1):308. PubMed ID: 34271921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of RET (rearranged during transfection) variants and their downstream signal molecules in RET rearranged lung adenocarcinoma patients.
    Kim JO; Shin JY; Kim MY; Son KH; Jung CK; Kim TJ; Kim SY; Park JK; Sung SW; Bae SJ; Min HJ; Kang JH
    Surg Oncol; 2018 Mar; 27(1):106-113. PubMed ID: 29549897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Characteristics and Molecular Patterns of
    Zhang K; Chen H; Wang Y; Yang L; Zhou C; Yin W; Wang G; Mao X; Xiang J; Li B; Zhang T; Fei S
    Oncol Res; 2019 May; 27(5):575-582. PubMed ID: 30131091
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting ALK in Neuroendocrine Tumors of the Lung.
    Akhoundova D; Haberecker M; Fritsch R; Höller S; Kiessling MK; Rechsteiner M; Rüschoff JH; Curioni-Fontecedro A
    Front Oncol; 2022; 12():911294. PubMed ID: 35756632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
    Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
    Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid and Cost-Efficient Detection of
    Tiurin VI; Preobrazhenskaya EV; Mitiushkina NV; Romanko AA; Anuskina AA; Mulkidjan RS; Saitova ES; Krivosheyeva EA; Kharitonova ED; Shevyakov MP; Tryakin IA; Aleksakhina SN; Venina AR; Sokolova TN; Martianov AS; Shestakova AD; Ivantsov AO; Iyevleva AG; Imyanitov EN
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445709
    [No Abstract]   [Full Text] [Related]  

  • 17. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
    Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
    Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
    Lin C; Shi X; Yang S; Zhao J; He Q; Jin Y; Yu X
    Lung Cancer; 2019 May; 131():62-68. PubMed ID: 31027700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.
    Pekar-Zlotin M; Hirsch FR; Soussan-Gutman L; Ilouze M; Dvir A; Boyle T; Wynes M; Miller VA; Lipson D; Palmer GA; Ali SM; Dekel S; Brenner R; Bunn PA; Peled N
    Oncologist; 2015 Mar; 20(3):316-22. PubMed ID: 25721120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
    Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
    Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.